Adial Pharmaceuticals, Inc. - נכסים נקיים למניה בודדת ADIL

Adial Pharmaceuticals specializes in alcohol dependence therapy, offering the drug AD04 for individuals with a genetic predisposition. The growth rate of the stock's book value demonstrates capital protection dynamics, where -14.55 reflects the latest metric value. A strong team of scientists and clinical experts ensures stable R&D development. The current lack of profit is attributed to the product development stage.

For Adial Pharmaceuticals (ADIL), which is developing an addiction therapy ecosystem with the drug AD04, this metric reflects the net equity value per share after deducting all liabilities. An analysis of the average book value per share allows for an assessment of the company's actual asset base, where capital dynamics serve as an indicator of the business's financial stability during periods of market consolidation.